ZORYVE is uniquely formulated as an emollient, water-based product without fragrances or penetration enhancers ... and pediatric patients 6 years of age and older. IMPORTANT SAFETY INFORMATION ZORYVE ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...

That means that if you haven’t gotten vaccines already, it’s time to put them on your to-do list. But which ones should you ...

GSK's vaccine sales, including RSV and Shingrix, decline amid changing US recommendations, impacting Q3 performance and ...

However, sales across critical divisions were lackluster, with key products such as the respiratory syncytial virus (RSV) vaccine, Arexvy, missing expectations by 21%, and Shingrix sales falling ...

Arexvy sales fell 72 per cent to £188million ... helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, as well as the resilience we have now ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third ... currently planning launches for five major new product approval opportunities next year.” ...